Ovarian injury is the fundamental cause of ovarian fibrosis. These injuries may include factors such as inflammation, immune abnormalities, and surgery. Fibrosis occurs as a consequence of increased ECM deposition due to deregulated wound-healing response. This phenomenon has not been extensively studied by researchers. Ovarian fibrosis plays a key role in the pathophysiological processes occurring in the ovary, and thus needs to be studied.
Pathological features of ovarian fibrosis are decreased or absent follicles, thick ovarian capsule, and increased mesenchymal connective tissue. Studies demonstrate the role of several cytokines; matrix metalloproteinases, connective tissue growth factor and several other factors are involved in the development of fibrosis. These factors mutually act to disrupt the balance between ECM synthesis and degradation. They also cause excessive proliferation of ovarian mesenchymal fibroblasts and increased ECM deposition. The current treatment scenario includes surgery coupled with taxol- and platinum-based chemotherapy.
In case of ovarian fibrosis the response of patients to treatment is difficult to predict and there need to be measures to assess the impacts of this treatment.
OVARIAN FIBROSIS DAY 21
UTERINE FIBROSIS DAY 21
All the drug combinations significantly reduced the fibrotic characteristics in
both uterine and ovarian models. The effect was very visible during the acute phase of the experimentation where various combinations successfully decreased the fibrosis characteristics within 3 days of treatment period, the decrease was ranging between 28.43% to 41.33% in Uterine model and 19.05% to 29.09% in ovarian model. With increase in incubation period till 21 days the range of percent reduction 42.94% to 60.47% in uterine system and 43.01% to 52.19% in ovarian model.
The effect of fibrotic reduction was dose dependent, incubation period and combination dependent, with the acute effect these effects were very extraordinary at incredibly low concentrations of 5ug/ml. The combination of Abronym, Zerilox and Turmeric was proven to be the most effective at all treatment time points and at all possible concentrations.
One can conclude that mentioned drugs have shown a particularly good effect on a disease cell types which is difficult to tackle and can suggest that wide use of these mentioned ayurvedic drugs for similar issues. Furthermore, the molecular analysis of the current effect should be pursued in future studies by adding more markers, other than in vitro studies the mouse models should also be analyzed.